These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 33778281)

  • 1. miR-486-5p: A Prognostic Biomarker for Chronic Myeloid Leukemia.
    Ninawe A; Guru SA; Yadav P; Masroor M; Samadhiya A; Bhutani N; Gupta N; Gupta R; Saxena A
    ACS Omega; 2021 Mar; 6(11):7711-7718. PubMed ID: 33778281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. De-regulated STAT5A/miR-202-5p/USP15/Caspase-6 regulatory axis suppresses CML cell apoptosis and contributes to Imatinib resistance.
    Nie ZY; Yao M; Yang Z; Yang L; Liu XJ; Yu J; Ma Y; Zhang N; Zhang XY; Liu MH; Jiang LL; Luo JM
    J Exp Clin Cancer Res; 2020 Jan; 39(1):17. PubMed ID: 31952546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LncRNA SNHG5 regulates imatinib resistance in chronic myeloid leukemia via acting as a CeRNA against MiR-205-5p.
    He B; Bai Y; Kang W; Zhang X; Jiang X
    Am J Cancer Res; 2017; 7(8):1704-1713. PubMed ID: 28861326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. microRNA-199a/b-5p enhance imatinib efficacy via repressing WNT2 signaling-mediated protective autophagy in imatinib-resistant chronic myeloid leukemia cells.
    Chen PH; Liu AJ; Ho KH; Chiu YT; Anne Lin ZH; Lee YT; Shih CM; Chen KC
    Chem Biol Interact; 2018 Aug; 291():144-151. PubMed ID: 29890129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circ_0009910 promotes imatinib resistance through ULK1-induced autophagy by sponging miR-34a-5p in chronic myeloid leukemia.
    Cao HX; Miao CF; Sang LN; Huang YM; Zhang R; Sun L; Jiang ZX
    Life Sci; 2020 Feb; 243():117255. PubMed ID: 31923418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression differences of miR-142-5p between treatment-naïve chronic myeloid leukemia patients responding and non-responding to imatinib therapy suggest a link to oncogenic ABL2, SRI, cKIT and MCL1 signaling pathways critical for development of therapy resistance.
    Klümper T; Bruckmueller H; Diewock T; Kaehler M; Haenisch S; Pott C; Bruhn O; Cascorbi I
    Exp Hematol Oncol; 2020; 9():26. PubMed ID: 32999756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identifying and validating a combined mRNA and microRNA signature in response to imatinib treatment in a chronic myeloid leukemia cell line.
    Bhutra S; Lenkala D; LaCroix B; Ye M; Huang RS
    PLoS One; 2014; 9(12):e115003. PubMed ID: 25506832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MiRNA-409-5p dysregulation promotes imatinib resistance and disease progression in children with chronic myeloid leukemia.
    Liu YY; Jiao WY; Li T; Bao YY
    Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8468-8475. PubMed ID: 31646577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation.
    Huang T; Fu Y; Wang S; Xu M; Yin X; Zhou M; Wang X; Chen C
    Biomed Pharmacother; 2019 Nov; 119():109413. PubMed ID: 31518872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-1301-Mediated RanGAP1 Downregulation Induces BCR-ABL Nuclear Entrapment to Enhance Imatinib Efficacy in Chronic Myeloid Leukemia Cells.
    Lin TY; Chen KC; Liu HJ; Liu AJ; Wang KL; Shih CM
    PLoS One; 2016; 11(5):e0156260. PubMed ID: 27228340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Silencing of suppressor of cytokine signaling-3 due to methylation results in phosphorylation of STAT3 in imatinib resistant BCR-ABL positive chronic myeloid leukemia cells.
    Al-Jamal HA; Jusoh SA; Yong AC; Asan JM; Hassan R; Johan MF
    Asian Pac J Cancer Prev; 2014; 15(11):4555-61. PubMed ID: 24969884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effect of imatinib and ponatinib on autophagy and miRNome in chronic myeloid leukemia.
    Kayabasi C; Okcanoglu TB; Yelken BO; Asik A; Susluer SY; Avci CB; Saydam G; Gunduz C
    Gene; 2017 Dec; 637():173-180. PubMed ID: 28942039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of
    Deng Y; Li X; Feng J; Zhang X
    Biosci Rep; 2018 Jun; 38(3):. PubMed ID: 29559564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA-141-5p Acts as a Tumor Suppressor
    Bao J; Li X; Li Y; Huang C; Meng X; Li J
    Front Pharmacol; 2019; 10():1545. PubMed ID: 32038235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Profile of BCR-ABL transcript levels based on Sokal prognostic score in chronic myeloid leukemia patients treated with imatinib.
    Ashariati A; Ugroseno S
    Acta Med Indones; 2013 Apr; 45(2):107-13. PubMed ID: 23770790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-101 sensitizes K562 cell line to imatinib through Jak2 downregulation and inhibition of NF-κB target genes.
    Farhadi E; Zaker F; Safa M; Rezvani MR
    Tumour Biol; 2016 Oct; 37(10):14117-14128. PubMed ID: 27517565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
    Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
    Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells.
    Venturini L; Battmer K; Castoldi M; Schultheis B; Hochhaus A; Muckenthaler MU; Ganser A; Eder M; Scherr M
    Blood; 2007 May; 109(10):4399-405. PubMed ID: 17284533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BCR-ABL/GATA1/miR-138 mini circuitry contributes to the leukemogenesis of chronic myeloid leukemia.
    Xu C; Fu H; Gao L; Wang L; Wang W; Li J; Li Y; Dou L; Gao X; Luo X; Jing Y; Chim CS; Zheng X; Yu L
    Oncogene; 2014 Jan; 33(1):44-54. PubMed ID: 23208504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Down-regulation of miR-199b associated with imatinib drug resistance in 9q34.1 deleted BCR/ABL positive CML patients.
    Joshi D; Chandrakala S; Korgaonkar S; Ghosh K; Vundinti BR
    Gene; 2014 Jun; 542(2):109-12. PubMed ID: 24680705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.